Neville Davidson

13.3k total citations · 2 hit papers
25 papers, 5.0k citations indexed

About

Neville Davidson is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Neville Davidson has authored 25 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 7 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Neville Davidson's work include HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (6 papers) and CAR-T cell therapy research (5 papers). Neville Davidson is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (6 papers) and CAR-T cell therapy research (5 papers). Neville Davidson collaborates with scholars based in United Kingdom, United States and France. Neville Davidson's co-authors include Paul Bhar, Michael Hawkins, Heather Shaw, William J. Gradishar, Joyce O’Shaughnessy, Sergei Tjulandin, Neil Desai, Charles E. Geyer, David Cameron and Agnieszka Jagiełło-Gruszfeld and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Neville Davidson

25 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

2006 2.5k citations Charles E. Geyer, Deborah Lindquist et al. New England Journal of Medicine profile →
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

2005 1.6k citations William J. Gradishar, Sergei Tjulandin et al. Journal of Clinical Oncology profile →

Peers

Neville Davidson

ONCOL

PRM

RNMI

John Gutheil United States

Lowell L. Hart United States

Ferry A.L.M. Eskens Netherlands

Hilary Calvert United Kingdom

Beth Overmoyer United States

Christian Dittrich Austria

Kirsten B. Goldberg United States

Joyce O’Shaughnessy United States

Sergei Tjulandin Russia

Anatoly Makhson Russia

John Gutheil United States

Neville Davidson

2.3k ×0.6

ONCOL

1.1k ×0.9

820 ×0.7

PRM

1.2k ×1.4

RNMI

457 ×0.6

Citations per year, relative to Neville Davidson Neville Davidson (= 1×) peers John Gutheil

Countries citing papers authored by Neville Davidson

Since Specialization

Citations

This map shows the geographic impact of Neville Davidson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neville Davidson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neville Davidson more than expected).

Fields of papers citing papers by Neville Davidson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neville Davidson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neville Davidson. The network helps show where Neville Davidson may publish in the future.

Co-authorship network of co-authors of Neville Davidson

This figure shows the co-authorship network connecting the top 25 collaborators of Neville Davidson. A scholar is included among the top collaborators of Neville Davidson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neville Davidson. Neville Davidson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Battisti, Nicolò Matteo Luca, Belinda Kingston, Judy King, et al.. (2019). Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. Breast Cancer Research and Treatment. 174(3). 731–740. 15 indexed citations

Corrie, Pippa, Andrea Marshall, Janet Dunn, et al.. (2014). Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. The Lancet Oncology. 15(6). 620–630. 75 indexed citations

Palmieri, Carlo, Vivek Misra, Adam Januszewski, et al.. (2013). Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer. Clinical Breast Cancer. 14(2). 85–93. 11 indexed citations

Payne, Miranda, Paul Lorigan, David Farrugia, et al.. (2013). Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence. Journal of Clinical Oncology. 32(3). 185–190. 24 indexed citations

Corrie, Pippa, Andrea Marshall, Janet Dunn, et al.. (2013). Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. Journal of Clinical Oncology. 31(18_suppl). LBA9000–LBA9000. 2 indexed citations

Sebag‐Montefiore, David, Helen Meadows, David Cunningham, et al.. (2012). Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): Long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. Radiotherapy and Oncology. 104(2). 155–160. 23 indexed citations

Gümüş, Mahmut, Neville Davidson, Thomas Bauknecht, Victoria Soldatenkova, & Karim A. Benhadji. (2011). Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study. Current Medical Research and Opinion. 28(3). 401–413. 3 indexed citations

Davidson, Neville, et al.. (2011). Rectal Small Cell Carcinoma: A Case Report and Review of the Literature. SHILAP Revista de lepidopterología. 4(3). 475–480. 10 indexed citations

Patel, Poulam M., Stefan Suciu, Laurent Mortier, et al.. (2011). Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). European Journal of Cancer. 47(10). 1476–1483. 142 indexed citations

10.

Papageorgiou, K., et al.. (2009). Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report. Cases Journal. 2(1). 9143–9143. 6 indexed citations

11.

Kamel, Dia, et al.. (2009). Late cutaneous metastases to the face from malignant pleural mesothelioma: A case report and review of the literature. World Journal of Surgical Oncology. 7(1). 84–84. 13 indexed citations

12.

Bundred, Nigel, Ian Campbell, Neville Davidson, et al.. (2008). Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. Cancer. 112(5). 1001–1010. 174 indexed citations

13.

Geyer, Charles E., Deborah Lindquist, Stephen Chan, et al.. (2006). Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 355(26). 2733–2743. 2498 indexed citations breakdown →

14.

Agrawal, Samir, Neville Davidson, Mel Walker, et al.. (2006). Assessing the total costs of blood delivery to hospital oncology and haematology patients. Current Medical Research and Opinion. 22(10). 1903–1909. 24 indexed citations

15.

Gradishar, William J., Sergei Tjulandin, Neville Davidson, et al.. (2005). Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer. Journal of Clinical Oncology. 23(31). 7794–7803. 1571 indexed citations breakdown →

16.

Ruff, Paul, Bernardo L. Rapoport, Stephen Falk, et al.. (2004). Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer. 4(1). 36–36. 8 indexed citations

17.

Douillard, Jean‐Yves, Paulo M. Hoff, Jamey Skillings, et al.. (2002). Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer. Journal of Clinical Oncology. 20(17). 3605–3616. 249 indexed citations

18.

Davidson, Neville, Bernardo L. Rapoport, Björn Erikstein, et al.. (1999). Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: A multicenter, double-masked study. Clinical Therapeutics. 21(3). 492–502. 25 indexed citations

19.

Davidson, Neville, et al.. (1990). Advanced ovarian cancer: Long-term results following chemotherapy and second-look laparotomy. Gynecologic Oncology. 39(3). 295–299. 3 indexed citations

20.

Balsitis, M, et al.. (1989). Systemic Metastasis from Primary Intracranial Germinoma: A case report and literature review. British Journal of Neurosurgery. 3(6). 717–723. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact